Every Form 4 that CNS Pharmaceuticals, Inc. (CNSP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CNSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNSP filings page.
CNS Pharmaceuticals, Inc. director Michal Fisher reported an open-market purchase of company stock. On May 18, 2026, Fisher purchased 2,000 shares of CNSP common stock at $5.00 per share. Following this transaction, Fisher directly holds 2,000 common shares of the company.
Levin Rami reported disposition transactions in this Form 4 filing.
CNS Pharmaceuticals, Inc. executive Rami Levin reported the vesting and conversion of 4,750 Restricted Stock Units into 4,750 shares of Common Stock on August 14, 2026. Each RSU represents a contingent right to one share of common stock. The RSUs stem from a 19,000-unit grant made on January 1, 2026, which vests 25% at six months, 25% at twelve months, and the remaining 50% in twelve quarterly installments, subject to continued employment. Following this transaction, Levin holds 14,250 RSUs and 4,750 shares of Common Stock directly, and the filing indicates these transactions were not made under a Rule 10b5-1 trading plan.
CNS Pharmaceuticals director Charles L. Faith reported an open-market purchase of 7,100 shares of Common Stock. The shares were bought at a price of $4.789 per share on May 18, 2026, and he now directly holds 7,100 shares following this transaction.
Faulkner Eric reported acquisition or exercise transactions in this Form 4 filing.
CNS Pharmaceuticals granted Chief Technology Officer Eric Faulkner 9,500 restricted stock units on March 2, 2026. Each unit represents a contingent right to receive one share of common stock. The award was issued in connection with his employment.
The RSUs vest over time: 25% after six months, another 25% after twelve months, and the remaining 50% in twelve quarterly installments thereafter, provided he remains employed on each vesting date. This is a stock-based compensation grant rather than an open-market share purchase.
O'Loughlin Steve reported acquisition or exercise transactions in this Form 4 filing.
CNS Pharmaceuticals, Inc. reported that Chief Financial Officer Steve O'Loughlin received a grant of 9,500 restricted stock units on March 2, 2026. Each restricted stock unit represents a contingent right to receive one share of the company’s common stock, issued in connection with his employment.
The award vests over time: 25% on the six-month anniversary of the grant date, another 25% on the twelve-month anniversary, and the remaining 50% in twelve quarterly installments thereafter, subject to his continued employment on each vesting date. Following this grant, he holds 9,500 restricted stock units directly.
CNS Pharmaceuticals, Inc. (CNSP) reported a Form 4 showing a director received an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share. The option was originally approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan, which shareholders granted on November 17, 2025. The option becomes exercisable in four equal quarterly installments starting on the November 17, 2025 shareholder approval date, as long as the director continues in employment on each vesting date, and expires on November 17, 2035. The filing states the option was issued in connection with the reporting person’s employment and is held as a direct ownership position.
CNS Pharmaceuticals, Inc. (CNSP) reported a Form 4 filing for a director covering a new stock option grant. The derivative security is an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, expiring on November 17, 2035.
The grant was approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan. Shareholders approved the plan at the annual meeting on November 17, 2025, defined as the “Shareholder Approval Date.” The options vest in four equal quarterly installments starting on the Shareholder Approval Date, contingent on the reporting person’s continued employment. After this transaction, the reporting person beneficially owns 1,517 derivative securities directly.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to its chief executive officer and director on a Form 4. The filing shows an option to purchase 9,761 shares of common stock at an exercise price of $30 per share, dated 11/17/2025 and expiring on 11/17/2035.
The option was originally approved on 03/11/2025, subject to shareholder approval of the stock option plan, which was obtained on 11/17/2025. The grant vests over 18 months: 50% on the six‑month anniversary of the grant date, 25% on the 12‑month anniversary, and 25% on the 18‑month anniversary, conditioned on continued employment. The reporting person beneficially owns 9,761 derivative securities directly after this transaction.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant on a Form 4 for a director. The filing shows an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, approved by the compensation committee on June 6, 2025 and made effective upon shareholder approval on November 17, 2025. The option vests in four equal quarterly installments beginning on the shareholder approval date, contingent on continued employment at each vesting date, and carries an expiration date of November 17, 2035. The option was issued in connection with the reporting person’s employment with the company.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to a director on a Form 4. The filing shows an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, dated 11/17/2025 with an expiration date of 11/17/2035.
The grant was originally approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan. Shareholders approved the plan at the annual meeting on November 17, 2025, which is also the “Shareholder Approval Date.” The options vest in four equal quarterly installments starting on that approval date, conditioned on the director’s continued service with the company.
CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to one of its directors on Form 4. On November 17, 2025, the director received an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, with an expiration date of November 17, 2035.
The option was originally approved by the compensation committee on June 6, 2025, and became effective after shareholders approved the underlying stock option plan on November 17, 2025, described as the Shareholder Approval Date. The options vest in four equal quarterly installments starting on that approval date, conditioned on the director’s continued employment with the company. The filing notes that the option was issued in connection with the reporting person’s employment and is held as a direct ownership position.
CNS Pharmaceuticals, Inc. reported an equity compensation grant to its Chief Financial Officer, Christopher Downs, on a Form 4. The filing shows an option to purchase 4,881 shares of common stock at a conversion or exercise price of $30 per share, with no price paid for the option itself. The option was approved by the compensation committee on the March 11, 2025 grant date, subject to shareholder approval of the stock option plan.
CNS Pharmaceuticals’ shareholders approved the plan at the annual meeting on November 17, 2025, making the grant effective. The options vest over 18 months, with 50% vesting on the six-month anniversary of the grant date, 25% on the 12-month anniversary, and 25% on the 18-month anniversary, conditioned on the CFO’s continued employment with the company.